The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Moderna Inc (NASDAQ: MRNA) closed at $26.72 in the last session, up 3.57% from day before closing price of $25.80. In other words, the price has increased by $3.57 from its previous closing price. On the day, 11.27 million shares were traded.
Ratios:
We take a closer look at MRNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.14 and its Current Ratio is at 4.22. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Neutral rating and assigned the stock a target price of $40.
On February 18, 2025, Barclays Downgraded its rating to Equal Weight which previously was Overweight and also lowered its target price recommendation from $111 to $45.
Goldman Downgraded its Buy to Neutral on January 29, 2025, whereas the target price for the stock was revised from $99 to $51.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 03 ’25 when Bancel Stephane bought 160,314 shares for $31.22 per share. The transaction valued at 5,004,318 led to the insider holds 9,210,686 shares of the business.
SAGAN PAUL bought 31,620 shares of MRNA for $1,004,251 on Mar 03 ’25. The Director now owns 312,027 shares after completing the transaction at $31.76 per share. On Dec 09 ’24, another insider, Klinger Shannon Thyme, who serves as the Chief Legal Officer of the company, sold 529 shares for $44.68 each. As a result, the insider received 23,637 and left with 20,446 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.25 while its Price-to-Book (P/B) ratio in mrq is 1.03.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $170.47, while it has fallen to a 52-week low of $23.15. The 50-Day Moving Average of the stock is -3.84%, while the 200-Day Moving Average is calculated to be -41.42%.
Shares Statistics:
A total of 387.00M shares are outstanding, with a floating share count of 342.49M. Insiders hold about 11.44% of the company’s shares, while institutions hold 72.18% stake in the company.
